1. Merck Sharp + Dohme Corp. (18 from 2,405 patents)

2. Lycera Corporation (6 from 36 patents)

1. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

2. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

3. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

4. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof

5. 10584121 - Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof

6. 10377768 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

7. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof

8. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof

9. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof

10. 10221146 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

11. 10196354 - 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof

12. 9809561 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

13. 9745265 - 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof

14. 9663502 - 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease

15. 9663522 - 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof